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Abstract
Background: The objective of present study was to provide the pharmacological basis for the medicinal use of
Morinda citrifolia Linn in dyslipidemia using the aqueous-ethanolic extracts of its fruits (Mc.Cr.F), leaves (Mc.Cr.L) and
roots (Mc.Cr.R).
Results: Mc.Cr.F, Mc.Cr.L and Mc.Cr.R showed antidyslipidemic effects in both triton (WR-1339) and high fat diet-
induced dyslipidemic rat models to variable extents. All three extracts caused reduction in total cholesterol and
triglyceride levels in triton-induced dyslipidemia. In high fat diet-induced dyslipidemia all these extracts caused
significant reduction in total cholesterol, triglyceride, low density lipoprotein-cholesterol (LDL-C), atherogenic index
and TC/HDL ratio. Mc.Cr.R extract also caused increase in high density lipoprotein-cholesterol (HDL-C). The Mc.Cr.L
and Mc.Cr.R reduced gain in body weight with a reduction in daily diet consumption but Mc.Cr.F had no effect on
body weight and daily diet consumption.
Conclusions: These data indicate that the antidyslipidemic effect of the plant extracts was meditated through the
inhibition of biosynthesis, absorption and secretion of lipids. This may be possibly due partly to the presence of
antioxidant constituents in this plant. Therefore, this study rationalizes the medicinal use of Morinda citrifolia in
dyslipidemia.
Background
Dyslipidemia is an independent and modifiable risk
factor for cardiovascular diseases. Its prevalence is
growing not only in developed countries but also in
developing countries [1]. Treatment of dyslipidemia
reduces cardiovascular events [2]. The modern phar-
macological therapy for abnormal lipids is effective but
is costly and associated with side-effects [3] leading to
patient incompliance. Therefore, alternative therapies
particularly, herbal based are being explored. Morinda
citrifolia Linn (Fam. Rubiaceae) is commonly known as
Noni. Different parts of the plant including fruit,
leaves, root, stem and bark are used in folk medicine
in Polynesia, Tahiti, Southeast Asia, Australia and
Hawaii. It has been shown that these are effective
against minimizing the symptoms of life style-related
diseases such as atherosclerosis [4], hypertension [5]
and other vascular disorders [4], stroke [6], diabetes
and cancer [7]. Furthermore, Noni juice, a popular
beverage is known to contain some antioxidative and
anti-inflammatory ingredients [5].
Morinda citrifolia, has been reported to possess vaso-
dilatory [8,9], antioxidant [10] antitumor [11] and
Angiotensin Converting Enzyme inhibitor activities[12].
It is an edible plant and its fruit juice is a popular drink.
Almost all parts of this plant have some medicinal value
and have been widely studied phytochemically [see addi-
tional file 1].
Recently we have reported that antispasmodic and
vasodilatory activities of Morinda citrifolia root extract
are mediated through blockade of voltage-dependent
calcium channels [9]. However, the plant is not widely
studied for its antidyslipidemic effects except a prelimin-
ary report [13]. Therefore, the objective of the present
study was to investigate the antidyslipidemic effect of
Morinda citrifolia in Triton WR 1339 and high fat diet-
induced dyslipidemia rat models to rationalize its medic-
inal use in cardiovascular disorders. * Correspondence: anwar.gilani@aku.edu
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Plant material
The vacuum dried 70% aqueous-ethanolic extract of
Morinda citrifolia fruit, leaves and roots were gifted by
the Sami Labs Limited 19/1, 19/2, 1st Main II Phase,
P e e n y aI n d u s t r i a lA r e a ,B a n g a l o r - 5 6 00 5 8 ,I n d i a .T h e
extracts were prepared by following procedure as
described by the manufacturer. Dried leaves, fruit and
roots of Morinda citrifolia were procured from a
reputed herb supplier in Southern India. The leaves,
fruits and roots were chopped and ground by hammer
mill and passed through 20 mesh screen. The powder
(12 Kg) was extracted with 70% ethanol (48 L) at 70°C
for 3 hours and filtered. The procedure repeated twice
and all filtrates combined and evaporated under
vacuum. The dried extracts were packed in polythene
bags with nitrogen purge.
Drugs and standards
The following reference chemicals were obtained from
the source specified: Triton (tyloxapol), Cholic acid,
cholesterol (Sigma Chemical Company, ST Louis, MO,
USA) and diethylether (Sigma-Aldrich Chemie GmbH,
Germany). Commercial Randox diagnostic kits were
used for serum analyses of total cholesterol (TC), trigly-
ceride (TG), high density lipoprotein-cholesterol (HDL-
C) and glucose level (Randox Laboratories Ltd., Co.
Antrim, UK). All chemicals used were of the highest
purity grade.
Animals
Sprague-Dawley (SD) rats (180-220 g) and mice (20-25
g) of either sex were obtained from the animal house of
the Aga Khan University, Karachi. The animals were
housed in constant room temperature (23-25°C), kept in
plastic cages (47 × 34 × 18 cm
3) with sawdust (renewed
after every 48 h) and had free access to food and water.
Rats were starved for 16 hrs prior to experiment, anaes-
thetized with diethyl ether by inhalation and blood was
collected via cardiac puncture. Experiments performed
with the rulings of the Institute of Laboratory Animal
Resources, Commission on Life Sciences [14].
Preparation of diet
The following two types of diets were prepared.
1. Normal diet: The normal diet was prepared at
the animal house of the Aga Khan University (AKU),
Karachi. The standard diet consists of flour (5 kg),
chokar (5 kg), salt (75 g), nutrivet L (33 g), molasses
(150 g), potassium meta bisulphate (15 g), fish meal
(2.25 kg), powdered milk (2 kg) and oil (500 g) for a
total of about 15 kg of the food material.
2. Atherogenic diet: Cholesterol (2% w/w), cholic
acid (0.5% w/w) and butter fat (5% w/w) were added
to normal diet, as described by Ichihashi [15] with
slight modification.
All measures were taken to ensure the uniform mixing
of additives in dry ingredients of the diet before
kneading.
Triton WR 1339-induced model of hyperlipidemia
The tyloxapol-induced hyperlipidemic model earlier
described by Khanna [16] was followed with slight mod-
ifications. Male SD rats weighing 180-220 g caged in
uniform hygienic conditions and kept on standard pellet
diet and water ad libitum. The rats were randomly
divided into 8 groups, each containing 6 rats, 1) control
group, 2) tritonized group (untreated) and 3-8) treated
groups with plant materials (Mc.Cr.F, Mc.Cr.R and Mc.
Cr.L). After 10 days of the treatment, all animals were
fasted for 7 h and group 1 received saline (10 ml/kg;
i.p.), while groups 2-8 were given tyloxapol (500 mg/kg;
i.p.). On the next day, rats were anaesthetized with
diethylether by inhalation and blood was collected via
cardiac puncture for analysis of serum total cholesterol
and triglycerides.
High fat diet-induced model
The high fat diet-induced dyslipidemic model was used
as earlier described [17] with slight modifications after
pilot studies. The adult SD rats (180-220 g) were ran-
domly divided into different groups, each containing 6
rats. Control group was given normal diet (served as
normal control), untreated group given atherogenic diet
(atherogenic control) and treated groups were given
atherogenic diet plus drug administered orally. All the
groups of animals had free access to water and diet. The
diet consumption was monitored daily and the gain in
body weight was monitored weekly. At the end of the
treatment, rats were fasted for 16 hrs, anaesthetized
with diethyl ether by inhalation, blood was collected via
cardiac puncture and serum analyzed for lipid profile
and glucose level.
Biochemical studies
Estimation of lipid profile and glucose level
For the determination of serum total cholesterol, high
density lipoprotein cholesterol, triglyceride and glucose,
a methods described by the manufacture (Randox
Laboratories Ltd., Co. Antrim, UK.) was used. For this
method test sample (serum), standard and blank were
pipetted using a micropipette in to eppendorf tube. The
reaction mixtures were mixed well and incubated at
20- 25°C. After incubation, 0.25 ml of each reaction
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bance was read at 490 nm against the reagent blank in
micro plate reader (Model 680 Bio-Rad Laboratories UK
Ltd). The concentration of absorbance was calculated
from the slope of concentration curve of the standards.
Estimation of LDL-C, TC/HDL and atherogenic index
These result were calculated indirectly by using formula
describe by [18].
LDL = TC - HDL - TG/5 and Atherogenic index=
TC-HDL/HDL.
Acute toxicity
The test was performed as described earlier [18]. Animals
were divided in different groups of 5 mice each and were
administered increasing doses of the plant extracts (3, 5,
10 g/kg, p.o.), in 10 ml/kg volume. Another group of
mice was administered saline (10 ml/kg, p.o.) served as a
negative control. The mice were allowed food and water
ad libitum during a 24 hr test period and kept under reg-
ular observation for gross behavioural changes and
mortality.
Data analysis
All data were expressed as mean ± standard error of
mean (SEM, n = number of experiments) and EC50
values are given as geometric mean with 95% confidence
intervals (CI). One-way Analysis of Variance (one-way
ANOVA) was used to compare the differences in means
of more than two groups, followed by Tukey post-test
to determine significant differences among the pairs.
P-values less than 0.05 (p < 0.05) were considered as
statistically significant. All the graphs, calculation and
statistical analyses were performed using GraphPad
Prism software version 4.00 for Windows (GraphPad
Software, San Diego California USA, http://www.graph-
pad.com).
Results
Effect of Morinda citrifolia extracts on tyloxapol-induced
hyperlipidemia
Administration of tyloxapol (triton WR-1339) caused a
significant increase (p < 0.001) in serum total cholesterol
and triglyceride of tritonized group as compared to ani-
mals in the control group. Pretreatment of the rats with
Mc.Cr.F (1000 mg/kg), Mc.Cr.L (1000 mg/kg) and Mc.
Cr.R (500 mg/kg) caused significant reduction in choles-
terol and triglyceride level. The data are summarized in
Table 1.
Effect of Fruit extract on high fat diet-induced
dyslipidemia
The intake of atherogenic diet increased serum total
cholesterol (TC), triglycer i d e ,L D L - C ,T C / H D Lr a t i o ,
atherogenic index and glucose level as compared to the
control group. The oral administration of fruit extract
(1000 mg/kg) with atherogenic diet prevented the rise in
serum TC, LDL-C, TC/HDL ratio and atherogenic
index. The treatment with the fruit extract had no sig-
nificant effect (p > 0.05) on the HDL-C and glucose
levels as compared to the atherogenic group. However,
there was no effect seen on body weight and daily diet
consumption (p > 0.05). The data are summarized in
Table 2.
Effect of leaves extract on high fat diet-induced
dyslipidemia
The TC, triglyceride, LDL-C, TC/HDL ratio, atherogenic
index and glucose levels of the atherogenic group were
significantly increased as compared to the control
group. Oral administration of leaves extract (1000 mg/
kg) with atherogenic diet prevented the rise of serum
T C ,L D L - C ,T C / H D Lr a t i o ,a t h e r o g e n i ci n d e xa n d
Table 1 Effect of Morinda citrifolia extracts on tyloxapol-
induced hyperlipidemia
Groups Total cholesterol
(mg/dl)
Triglyceride
(mg/dl)
Control 66.44 ± 4.84 94.36 ± 8.83
Tritonized 878.76 ± 15.20 5177.73 ± 318.92
Treatments
Mc.Cr.F 1000 mg/kg/day 565.83 ± 40.72** 3457.30 ± 275.13*
Mc.Cr.F 500 mg/kg/day 777.11 ± 80.32 4647.44 ± 237.38
Mc.Cr.L 1000 mg/kg/day 620.32 ± 39.32* 3693.55 ± 70.52*
Mc.Cr.L 500 mg/kg/day 699.00 ± 25.87 4110.84 ± 338.59
Mc.Cr.R 500 mg/kg/day 540.69 ± 107.57** 2997.02 ± 669.2***
Mc.Cr.R 300 mg/kg/day 844.0091 ± 44.32 4849.91 ± 167.52
Vale shown are mean ± S.E.M of 6 determinations
One-way ANOVA followed by Tukey post-test
*P< 0.05, **P < 0.01 and ***P < 0.001 compared to atherogenic group.
Table 2 Effect of Morinda citrifolia fruit extract (1000 mg/kg)
on high fat diet-induced hyperlipidemia
Parameters Control Atherogenic Treated
Total cholesterol (mg/dl) 67.48 ±
7.25
438.50 ±
22.87
284.5 ± 51.7*
Triglyceride (mg/dl) 72.08 ±
5.21
107.42 ±
10.97
64.89 ±
5.85**
HDL (mg/dl) 40.78 ±
6.38
12. 65 ± 2.76 21.1 ± 2.9
LDL (mg/dl) 12.37 ±
9.44
404.39 ± 21.0 250.3 ± 52.2*
TC/HDL ratio 1.84 ± 0.38 39.6 7 ± 7.28 14.81 ± 3.5*
Atherogenic index 0.71 ± 0.16 26.31 ± 3.31 7.71 ± 1.6***
Glucose (mg/dl) 88.85 ±
5.32
155.18 ±
10.56
125.8 ± 12.9
Diet consumption g/day 155.4 ± 7.5 122.3 ± 8.4 128.3 ± 6.9
% of change in body
weight
28.5 ± 2.6 55.9 ± 6.5 47.3 ± 4.1
Vale shown are mean ± S.E.M of 6 determinations
One-way ANOVA followed by Tukey post-test
*P < 0.05, **P < 0.01 and ***P < 0.001 compared to atherogenic group.
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in the atherogenic group. The leaves extract significantly
prevented the gain in average body weight and increased
daily diet consumption as compared to the atherogenic
group. The data are summarized in Table 3.
Effect of root extract on high fat diet-induced
dyslipidemia
The TC, triglyceride, LDL-C, TC/HDL ratio, atherogenic
index and glucose levels in the atherogenic group were
significantly increased as compared to the control
group. Oral administration of root extract (500 mg/kg)
w i t ha t h e r o g e n i cd i e tp r e v e n t e dt h er i s ei ns e r u mT C ,
LDL-C, TC/HDL ratio, atherogenic index and glucose
levels. The treatment with (500 mg/kg) also increased
HDL-C (p < 0.05) as compared to the atherogenic
group. The root extract significantly prevented the gain
in average body weight and increased daily diet
consumption as compared to the atherogenic group
(p < 0.001). The data are summarized in Table 4.
Safety study
The treatment with Morinda citrifolia fruit, leaves and
root extracts for 10 day (tyloxapol study) and 6 weeks
(high fat diet study) did not produce any death or beha-
vioural changes in rats.
Acute toxicity testing (24 hour time) of Mc.Cr.F and
Mc.Cr.L was conducted in mice at different doses (3, 5
and 10 g/kg) and there was no mortality or changes in
gross behaviour observed up to the dose of as high as
10 g/Kg, as compared to control group. The roots
extract (Mc.Cr.R) also did not cause any mortality and
changes in gross behaviour up to the dose of 10 g/Kg as
previously described [9].
Discussion
Morinda citrifolia has been considered useful in cardio-
vascular diseases particularly hypertension, atherosclero-
sis and dyslipidemia. In this study we used different
animal models to evaluate the possible mode of action
(s) of antidyslipidemic effect of different parts of
Morinda citrifolia. Tyloxapol is a non-ionic surfactant
being widely used to explore possible mechanism of
lipid lowering drugs, it causes drastic increase in serum
triglycerides and cholesterol levels due to increase in
hepatic cholesterol synthesis particularly by the increase
in HMG Co-A (3-hydroxy-3-methyl-glutaryl Co-A)
activity [19] and by the inhibition of lipoprotein lipase
responsible for hydrolysis of plasma lipids [20]. In fast-
ing condition the only source of serum lipid levels is the
endogenous production. Significant inhibition of rise in
lipid levels by extracts of various parts of Morinda
citrifolia in this model is indicative of inhibition of
cholesterol biosynthesis by inhibition of HMG Co-A.
This enzyme plays a key role in controlling lipid levels
in plasma and other tissue. Most of the newer antidysli-
pidemic drugs such as statins act via the inhibition of
HMG Co-A. However, failure of the Noni extracts to
cause complete inhibition indicates the involvement of
additional mechanisms. Morinda citrifolia is reported to
be rich in flavones [9,21,22], which are known to inhibit
lipid biosynthesis [23]. High cholesterol diet induces
endothelial dysfunction, atherosclerosis [24] and
increases oxidative stress by increasing the expression of
oxidation-sensitive genes, such as Elk-1 and p-CREB
Table 3 Effect of Morinda citrifolia leaves extract
(1000 mg/kg) on high fat diet induced hyperlipidemia
Parameters Control Atherogenic Treated
Total cholesterol (mg/dl) 81.02 ±
10.1
446.63 ± 40.0 235.3 ±
22.3***
Triglyceride (mg/dl) 70.94 ± 5.2 107.3 ± 11.0 70.52 ± 11.0*
HDL (mg/dl) 39.98 ±
5.86
13.26 ± 3.14 17.85 ± 3.77
LDL (mg/dl) 25.85 ±
10.7
412.21 ± 40.3 203.38 ±
24.2**
TC/HDL ratio 2.55 ± 0.46 37.37 ± 8.56 16.51 ± 3.65*
Atherogenic index 1.17 ± 0.41 31.10 ± 6.23 15.51 ± 3.65*
Glucose (mg/dl) 83.88 ±
6.83
158.81 ±
10.13
102.91 ±
5.21*
Diet consumption g/day 150.91 ±
8.44
120.3 ± 6.41 140.8 ± 9.3**
% of change in body
weight
25.04 ±
2.42
59.79 ± 3.68 26.50 ±
7.27***
Vale shown are mean ± S.E.M of 6 determinations
One-way ANOVA followed by Tukey post-test
*P < 0.05, **P < 0.01 and ***P < 0.001 compared to atherogenic group.
Table 4 Effect of Morinda citrifolia root extract (1000 mg/kg)
on high fat diet induced hyperlipidemia
Parameters Control Atherogenic Treated
Total cholesterol (mg/dl) 70.67 ±
5.76
384.81 ±
32.99
224.5 ±
26.6***
Triglyceride (mg/dl) 73.09 ±
5.21
109.42 ±
10.27
70.52 ±
10.99*
HDL (mg/dl) 43.34 ±
5.60
11.49 ± 3.26 43.82 ± 2.3***
LDL (mg/dl) 18.71 ±
5.21
351.44 ±
32.90
173.21 ±
2.0***
TC/HDL ratio 1.69 ± 0.15 52.01 ± 16.11 5.36 ± 0.83***
Atherogenic index 0.70 ± 0.2 24.41 ± 4.46 5.74 ± 2.11***
Glucose (mg/dl) 93.39 ± 5.4 157.67 ± 9.4 95.09 ± 9.0***
Diet consumption g/day 160.04 ±
5.5
118.3 ± 9.54 135.4 ± 8.7***
% of change in body
weight
30.5 ± 2.63 55.19 ± 4.58 17.34 ± 3.4***
Vale shown are mean ± S.E.M of 6 determinations
One-way ANOVA followed by Tukey post-test
*P < 0.05 and ***P < 0.001 compared to atherogenic group.
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LDL-C, atherogenic index and decrease HDL-C by
enhancing intestinal absorption and secretion and
decreasing catabolism of cholesterol [26]. Treatment
with Morinda citrifolia extracts caused a significant
decrease in mean serum TC and LDL-C while increased
HDL-C. The plant extracts also caused significant
reduction in the atherogenic index, which is considered
a better indicator of coronary heart disease risk than
individual lipoprotein concentration [27].
High fat diet also causes oxidative stress (enzymatic
and non-enzymatic) in rats, thus, increases oxidation of
low density lipoprotein (LDL) which plays key role in
genesis of atherosclerosis. Antioxidants are known to
effectively prevent this kind of damage [28]. The presence
of strong antioxidant activities in various parts of Mor-
inda citrifolia [29] may offer additional benefit in com-
bating the oxidative stress caused by high cholesterol.
Relatively strong antidyslipidemic activity in root extract
may be due to the presence of more antioxidant activity
in this part [10,29]. The active constituents responsible
for antioxidant activity include 3,3’-bisdemethylpinoresi-
nol, americanol A, morindolin, isoprincepin [30], scopo-
letin [31], kaempferol, ursolic acid, quercetin and various
other constituents [30,32-34] [see additional file 1]
Conclusions
The present study provides mechanisms of antidyslipi-
demic activities of various parts of Morinda citrifolia
through multiple pathways i.e., inhibition of biosynth-
esis, absorption and secretion of lipids. This may be due
to the presence of multiple potent antioxidant constitu-
ents in this plant, though additional mechanism(s) can-
not be ruled out. The results from this study rationalize
the medicinal use of Morinda citrifolia in dyslipidemia
and it can be used as a potential medicine for cardiovas-
cular diseases. However, further studies are required to
prove the safety and efficacy of Morinda citrifolia and
its constituents in actual clinical settings.
Additional material
Additional file 1: Chemical constituents from various parts of
Morinda Citrifolia. Following list shows reported chemical constituents
isolated from different parts of Morinda citrifolia plant.
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